Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden on the investment in Aprea AB
Mandate

Vinge advises Industrifonden on the investment in Aprea AB

November 07, 2007

Vinge advises Industrifonden on its investment in Aprea AB, a pharmaceutical company that develops and carries out research on a new drug against cancer. Aprea will raise MSEK 50 through this share issue of which Industrifonden contributes with MSEK 25 and will thereby become a new owner in the company.

Industrifonden is represented by partner Johan Winnerblad with assistance from Johan Larsson.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026